Modality
Fusion Protein
MOA
HPK1i
Target
FGFR
Pathway
Apoptosis
Atopic Derm
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Feb 2026
Phase 1Current
NCT06115428
2,872 pts·Atopic Derm
2018-03→TBD·Not yet recruiting
NCT05582140
1,396 pts·Atopic Derm
2018-07→2026-02·Completed
4,268 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-241mo agoInterim· Atopic Derm
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Not yet…
P1
Complet…
Catalysts
Interim
2026-02-24 · 1mo ago
Atopic Derm
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06115428 | Phase 1 | Atopic Derm | Not yet recr... | 2872 | ACR20 |
| NCT05582140 | Phase 1 | Atopic Derm | Completed | 1396 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |